Read More: Patients Are Suing Over Alleged Side Effects of Weight-Loss Drugs ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

Weight loss drugs catapulted many into a new wellness era ... of new drugs looking to enter the market. Between August 2021 and August 2023, the prevalence of obesity among adults was 40.3 ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

GLP-1 class of weight loss and diabetes drugs are linked to previously unrecognized health risks and benefits, according to a ...

About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...

Nearly half of US adults admit they’d take one of the newer, injectable weight loss ... 2021 to December 2023, of which 58.9% were female. The overall prevalence of discontinuation of GLP-1 ...

Industry lobbyists maintain that this will reduce investment in new pill medications even if they may be the most effective and affordable option for patients. In addition to the weight-loss ...

Research reveals groundbreaking results about Mounjaro and Ozempic in weight loss treatment. Here's what you need to know ...